Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $630.5 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $630.5 million, down 2.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $630.5 million (down 2.09% YoY), and the FY2025 annual result was $637.1 million, changed 0.31% from the prior year.
• Total Non-Current Liabilities came in at $630.5 million for Q1 2026 at Ironwood Pharmaceuticals, down from $637.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $919.0 million in Q2 2023 to a low of $436.3 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $637.1 million (2025), against an average of $631.5 million.
• Across the five-year window, Total Non-Current Liabilities surged 110.62% in 2023 and retreated 25.72% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Total Non-Current Liabilities stood at $438.4 million in 2022, then surged by 79.97% to $789.0 million in 2023, then decreased by 19.5% to $635.1 million in 2024, then climbed by 0.31% to $637.1 million in 2025, then retreated by 1.03% to $630.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $630.5 million (Q1 2026), $637.1 million (Q4 2025), and $638.0 million (Q3 2025), per Business Quant data.